Why Moderna Stock Blasted 13% Higher Today [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
The company, which developed and sells the Spikevax COVID-19 vaccine, saw its share price balloon by almost 13% thanks to an encouraging set of quarterly results. With that rise, it easily topped the 0.9% bump of the S&P 500 index on the day. Huge revenue drop and major net loss, as expected Moderna's opening quarter of 2024 saw the company reap $167 million in revenue, less than a tenth of the nearly $1.9 billion it made in the same period of 2023. The key reason why was simple and entirely expected: We're well past the peak of the Covid pandemic, after all, and there has been a sharp drop-off in demand for vaccines like Spikevax. Consequently, the company posted a rather deep headline net loss of almost $1.2 billion, or $3.07 per share, against the year-ago profit of $79 million ($0.19). Normally, investors wouldn't reward such declines and steep shortfalls. But the market was braced for a notably worse showing. On average, analysts following Moderna stock were estimating th
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy? [Yahoo! Finance]Yahoo! Finance
- Moderna wins COVID shot patent case against Pfizer-BioNTech in Europe [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech [Yahoo! Finance]Yahoo! Finance
- Moderna vaccine patent upheld by European Patent Office: report [Seeking Alpha]Seeking Alpha
- Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at Evercore ISI to a "hold" rating.MarketBeat
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 5/17/24 - Form 4
- 5/15/24 - Form 144
- 5/15/24 - Form 144
- MRNA's page on the SEC website